Evidence map›Paper›PMID 34045872›Full record

ReviewJournal of asthma and allergy2021

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction.

Manisha Ramphul, David K H Lo, Erol A Gaillard

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Biologic Therapies in Pediatric Asthma.Journal of personalized medicine · 2022
    Review
  2. Article
  3. Journal of asthma and allergy · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Manisha RamphulDepartment of Paediatric Respiratory Medicine, Leicester Children's Hospital, University Hospitals Leicester, Leicester, UK.ORCID 0000-0002-6209-3869
David K H LoDepartment of Paediatric Respiratory Medicine, Leicester Children's Hospital, University Hospitals Leicester, Leicester, UK.
Erol A GaillardDepartment of Paediatric Respiratory Medicine, Leicester Children's Hospital, University Hospitals Leicester, Leicester, UK.ORCID 0000-0003-0996-8133
University of Leicester · GBUniversity Hospitals of Leicester NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is a heterogeneous disease, characterised by different phenotypes and endotypes. Precision medicine in asthma refers to the implementation of a targeted therapy for each individual child, based on the identification of treatable traits, including environmental, immunological and genetic factors. Severe asthma in children is associated with increased hospitalisation rates, a lower quality of life, increased healthcare costs and an increased mortality. In the era of new molecular biologics treatments, it is essential to improve deep phenotyping of children with severe asthma in order to deliver the most effective treatment to each individual child. In this review, we discuss the personalised approach to the assessment and management of severe asthma. We explore the indications and use of the currently licensed biologics, as well as the potential of other emerging treatments.

Indexed as

benralizumabchilddupilumabmepolizumabomalizumabreslizumab

Identifiers

PMID34045872
PMCPMC8144021
OpenAlexW3160112410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.